For decades, CSL was the golden child of the ASX, the great Australian success story: a privatised government entity turned global biotech titan.

One day after CSL suddenly replaced its CEO, the company provided dismal financial figures that helped explain why. | One day after CSL revealed that it had suddenly replaced its CEO, the company ...

Formerly the Commonwealth Serum Laboratories, CSL grew under McNamee into a world leader in blood fractionation, where plasma ...

With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the ...

From a student in Iloilo to an internationally recognized authority in vaccinology, Dr. Melvin Sanicas, is an expert who not ...

Americans pay about three times what other wealthy nations do for branded prescription drugs. For years, policymakers have tried to fix this by cutting U.S. drug prices directly. President Trump has ...

Pharmaceutical executives are finally saying how they really feel about the extreme anti-vaccine agenda Health Secretary Robert F. Kennedy Jr. has been ruthlessly implementing—and it’s not pretty.

The rise of AI has powered a wave of interest in digital innovation within pharma. But to have a lasting impact, AI — like any innovation in digital health — must be able to deliver value by being ...

Drug development is notoriously failure-prone. Only one in every ten drug candidates that enter human trials eventually goes onto the market. Turning a promising molecule into a useful medicine ...

Some of the best-selling drugs in the world are facing a loss of exclusivity in key jurisdictions in the upcoming years in what the sector calls "the patent cliff." The need for pharma to top up their ...

The FDA approved Evrysdi in 2020 and has treated over 21,000 patients worldwide. In 2024, Evrysdi generated sales of approximately 1.6 billion Swiss francs ($1.9 billion), representing 18% ...